S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
Stop Day Trading - More Here (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
Stop Day Trading - More Here (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
Stop Day Trading - More Here (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
Stop Day Trading - More Here (Ad)pixel
NASDAQ:VRNA

Verona Pharma - VRNA Stock Forecast, Price & News

$13.59
+1.79 (+15.17%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$11.27
$13.86
50-Day Range
$3.85
$11.80
52-Week Range
$3.41
$14.69
Volume
1.64 million shs
Average Volume
390,409 shs
Market Capitalization
$820.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.00

Verona Pharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
84.0% Upside
$25.00 Price Target
Short Interest
Healthy
0.10% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.60mentions of Verona Pharma in the last 14 days
Based on 36 Articles This Week
Insider Trading
Selling Shares
$1.10 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.47) to ($1.37) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.20 out of 5 stars

Medical Sector

514th out of 1,117 stocks

Pharmaceutical Preparations Industry

252nd out of 550 stocks

VRNA stock logo

About Verona Pharma (NASDAQ:VRNA) Stock

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

Verona Pharma Trading Up 8.3 %

Shares of Verona Pharma stock opened at $11.80 on Friday. The firm's 50-day moving average is $5.16 and its 200 day moving average is $4.99. Verona Pharma has a 1 year low of $3.41 and a 1 year high of $14.69. The company has a current ratio of 3.57, a quick ratio of 4.04 and a debt-to-equity ratio of 0.05.

Analyst Ratings Changes

VRNA has been the topic of a number of recent research reports. Canaccord Genuity Group upped their price target on Verona Pharma from $24.00 to $27.00 and gave the company a "buy" rating in a research report on Wednesday. Wedbush boosted their price objective on shares of Verona Pharma from $18.00 to $23.00 in a report on Tuesday. Finally, HC Wainwright restated a "buy" rating and set a $25.00 target price on shares of Verona Pharma in a report on Tuesday, June 21st.

Insiders Place Their Bets

In other news, CEO David Zaccardelli sold 600,000 shares of the stock in a transaction that occurred on Tuesday, August 9th. The shares were sold at an average price of $1.75, for a total value of $1,050,000.00. Following the transaction, the chief executive officer now owns 15,263,560 shares in the company, valued at approximately $26,711,230. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last 90 days, insiders sold 674,824 shares of company stock valued at $1,102,377. 3.90% of the stock is owned by insiders.

Receive VRNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verona Pharma and its competitors with MarketBeat's FREE daily newsletter.

VRNA Stock News Headlines

Dow Drops Over 100 Points; Verona Pharma Shares Jump
Recap: Verona Pharma Q2 Earnings
Why Verona Pharma Stock Is Skyrocketing Today
Verona Pharma to Host KOL Event on June 16, 2022
See More Headlines
Receive VRNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verona Pharma and its competitors with MarketBeat's FREE daily newsletter.

VRNA Company Calendar

Last Earnings
10/29/2020
Today
8/13/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VRNA
Fax
N/A
Employees
24
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$25.00
High Stock Price Forecast
$27.00
Low Stock Price Forecast
$23.00
Forecasted Upside/Downside
+84.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-55,570,000.00
Pretax Margin
-136.94%

Debt

Sales & Book Value

Annual Sales
$40 million
Book Value
$1.82 per share

Miscellaneous

Free Float
58,014,000
Market Cap
$820.40 million
Optionable
Not Optionable
Beta
0.79

Key Executives














VRNA Stock - Frequently Asked Questions

Should I buy or sell Verona Pharma stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Verona Pharma in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VRNA shares.
View VRNA analyst ratings
or view top-rated stocks.

What is Verona Pharma's stock price forecast for 2022?

3 Wall Street analysts have issued 12 month price objectives for Verona Pharma's stock. Their VRNA share price forecasts range from $23.00 to $27.00. On average, they anticipate the company's share price to reach $25.00 in the next year. This suggests a possible upside of 84.0% from the stock's current price.
View analysts price targets for VRNA
or view top-rated stocks among Wall Street analysts.

How have VRNA shares performed in 2022?

Verona Pharma's stock was trading at $6.72 on January 1st, 2022. Since then, VRNA stock has increased by 102.2% and is now trading at $13.59.
View the best growth stocks for 2022 here
.

When is Verona Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our VRNA earnings forecast
.

How can I listen to Verona Pharma's earnings call?

Verona Pharma will be holding an earnings conference call on Monday, August 15th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Verona Pharma's earnings last quarter?

Verona Pharma plc (NASDAQ:VRNA) posted its quarterly earnings data on Thursday, October, 29th. The company reported ($0.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by $0.18.

What other stocks do shareholders of Verona Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Verona Pharma investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Trevena (TRVN), Pfizer (PFE), Citius Pharmaceuticals (CTXR), electroCore (ECOR), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), VBI Vaccines (VBIV) and Vaxart (VXRT).

When did Verona Pharma IPO?

(VRNA) raised $61 million in an initial public offering on Thursday, April 27th 2017. The company issued 4,500,000 shares at a price of $13.49 per share. Jefferies and Stifel acted as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers.

What is Verona Pharma's stock symbol?

Verona Pharma trades on the NASDAQ under the ticker symbol "VRNA."

Who are Verona Pharma's major shareholders?

Verona Pharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Ikarian Capital LLC (0.50%), D.A. Davidson & CO. (0.07%), Renaissance Technologies LLC (0.05%) and Forefront Analytics LLC (0.05%). Insiders that own company stock include Anders Ullman, David Zaccardelli, Kathleen A Rickard, Lisa Deschamps, Mark W Hahn, Mark W Hahn and Patrick John Finn.
View institutional ownership trends
.

How do I buy shares of Verona Pharma?

Shares of VRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Verona Pharma's stock price today?

One share of VRNA stock can currently be purchased for approximately $13.59.

How much money does Verona Pharma make?

Verona Pharma (NASDAQ:VRNA) has a market capitalization of $820.40 million and generates $40 million in revenue each year. The company earns $-55,570,000.00 in net income (profit) each year or ($0.95) on an earnings per share basis.

How can I contact Verona Pharma?

Verona Pharma's mailing address is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. The official website for the company is www.veronapharma.com. The company can be reached via phone at 011-44-0-2032834200 or via email at verona@argotpartners.com.

This page (NASDAQ:VRNA) was last updated on 8/13/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.